Latest news with #ShanghaiJiaoTongUniversitySchoolofMedicine
Business Wire
12 hours ago
- Health
- Business Wire
Zambon Announces Approval and Launch in China of the Intravenous Formulation of Fluimucil® (N-acetylcysteine)
MILAN--(BUSINESS WIRE)-- Zambon, a multinational chemical-pharmaceutical company founded on the history and values of an Italian family and committed to innovate cure and care to make patients' lives better, announces the approval by Chinese regulatory authorities and the launch on the Chinese market of the intravenous (IV) formulation of Fluimucil® (N-acetylcysteine). This milestone marks a significant step in the company's commitment to global therapeutic innovation in respiratory diseases, reflecting its dedicated focus on both clinical research and patient care. 'This approval is the result of a joint effort with local scientific communities and reinforces our commitment and sense of responsibility to improving patients' quality of life.' Share Already available in several international markets, Fluimucil® IV represents a new option for Chinese patients, where it can provide an important hospital-based therapeutic option for treating respiratory diseases characterized by excessive mucus secretion. The approval in China follows a locally conducted clinical development program, a Phase 1 and a Phase 3 clinical trial that confirmed the drug's safety, tolerability, and efficacy profile. The Phase 1 pharmacokinetics and tolerability study 1 of Fluimucil® IV in healthy volunteers, run at the Ruijin Hospital affiliated with the Shanghai Jiao Tong University School of Medicine and led by Prof. Yaozong Yuan, showed that single and multiple 600 mg doses of Fluimucil® IV were well tolerated and free from significant adverse events 2. A pivotal Phase 3 clinical trial 3 - started in June 2019 and concluded in February 2021 - involving 333 adult patients with respiratory diseases and abnormal mucus secretions across 28 hospital centers in China, and led by Prof. Jieming Qu, demonstrated that Fluimucil® IV (600 mg, twice daily) was significantly superior to placebo and non-inferior to intravenous ambroxol hydrochloride in reducing sputum viscosity and improving ease of expectoration after 7 days of treatment. The data also demonstrate that the drug is well tolerated 4. ' The approval of Fluimucil® IV in China is a major recognition of the scientific rigor with which we conducted the clinical trials and the quality of our collaboration with local research centers,' said Paola Castellani, Chief Medical Officer and Head of R&D at Zambon. ' We would like to sincerely express our gratitude to patients participating in our clinical studies, as well as to investigators for their commitment. ' ' We are proud to celebrate the 60 th anniversary of Fluimucil® by making its intravenous formulation available in China, confirming the long-standing efficacy of this molecule,' said Giovanni Magnaghi, CEO of Zambon. ' This approval is the result of a joint effort with local scientific communities and reinforces our commitment and sense of responsibility to improving patients' quality of life. ' The intravenous formulation of Fluimucil® will initially be distributed in a selection of Chinese hospitals and represents another step forward in Zambon's expansion strategy in the Chinese market.
Yahoo
09-05-2025
- Health
- Yahoo
Intermittent Fasting Linked To Higher Deadly Disease Risk—Here's What Experts Say
Most diets are about the food you eat, but intermittent fasting is about the time period in which you eat. Also referred to as time-restricted eating, intermittent fasting restricts when you eat—or don't—to a time period, which could be hours or a day. While previous research has shown potential benefits of the diet to lower blood pressure or help with weight loss, new research is saying otherwise. Last year, the research presented at the American Heart Association's scientific sessions in Chicago claimed that intermittent fasting can drastically increase the risk of dying from cardiovascular disease. According to research from Shanghai Jiao Tong University School of Medicine in China, restricting food consumption to less than eight hours per day increases the chances of cardiovascular death by a whopping 91 percent. While the analysis has not yet been peer-reviewed or published in an academic journal, the data was collected from the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey. The researchers reviewed responses from 20,000 adults on what they ate for at least two days. They then examined which of those participants died of cardiovascular disease after around eight years. However, co-author of the analysis, Victor Wenze Zhong, says that it still might be too early to take this information as a conclusion based on his research alone. "Practicing intermittent fasting for a short period such as three months may likely lead to benefits on reducing weight and improving cardiometabolic health," Zhong told NBC in an email. He added that people "should be extremely cautious" when practicing intermittent fasting for a longer amount of time, like years. Zhong added that he is unclear as to why there is an association between intermittent fasting and the risk of death from cardiovascular disease. He did say, however, that those who limit their eating to fewer than eight hours per day have a lower lean muscle mass than those that consume food for 12 to 16 hours—and low lean muscle mass is linked to a higher risk of cardiovascular death. A research professor at Intermountain Health in Salt Lake City, Dr. Benjamin Horne, also noted that fasting increases stress hormones like cortisol and adrenaline, which can also increase the risk of heart problems. You Might Also Like Insanely Easy Weeknight Dinners To Try This Week 29 Insanely Delicious Vodka Cocktails
